跳转至

动力抑制

◀返回

动力抑制（也被称为意志减退或动机缺乏）[1] 被定义为开始或坚持目标导向行为的欲望减少啦[2][3]。动力抑制让一个人无法把一个行动的奖赏价值维持到不确定的未来；这包括那些被认为有挑战性或不愉快的任务，比如工作、学习、打扫卫生和做家务。在程度比较高的时候，动力抑制会导致一个人失去参与任何活动的欲望，甚至包括那些通常被认为是有趣或有回报的活动呢。如果这种效应以高强度持续很长时间，可能会导致严重的无聊状态，甚至轻微的抑郁哦。

动力抑制通常还伴随着其他效应，比如镇静和思维减速。它最常在急性给药的抗精神病药影响下出现，比如喹硫平、氟哌啶醇和利培酮[4][5]。不过要注意的是，长期服用任何剂量的抗精神病药治疗并不会导致这种效应哦[1]。它也可能发生在严重剂量的大麻类物质[6]和苯二氮卓类物质的影响下，作为长期使用SSRI类药物的后果[7]，或者在兴奋剂的药效褪去期间，以及几乎任何化合物的药物戒断反应期间出现呢。

体验报告

在我们的体验报告中，描述了这种效应的轶事报告包括：

  • Experience:100-350mg - Phenylpiracetam in daily life
  • Experience:FMA (37.5 mg, oral) - Never been this productive in my life_-_Never_been_this_productive_in_my_life)
  • Experience:Marijuana Withdrawal
  • Experience:~150mg MDA(oral) - a case of mistaken identity_-_a_case_of_mistaken_identity)

另见

外部链接

参考文献

  1. ↑ 1.0 1.1 Fervaha, Gagan; Takeuchi, Hiroyoshi; Lee, Jimmy; Foussias, George; Fletcher, Paul J; Agid, Ofer; Remington, Gary (2015). "Antipsychotics and Amotivation". Neuropsychopharmacology. 40 (6): 1539–1548. doi:10.1038/npp.2015.3. ISSN 0893-133X.
  2. ↑ Lee, Jung; Jung, Suwon; Park, Il; Kim, Jae-Jin (2015). "Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System". Current Neuropharmacology. 13 (6): 750–759. doi:10.2174/1570159X13666150612230333. ISSN 1570-159X.
  3. ↑ Barch, D. M.; Dowd, E. C. (2010). "Goal Representations and Motivational Drive in Schizophrenia: The Role of Prefrontal-Striatal Interactions". Schizophrenia Bulletin. 36 (5): 919–934. doi:10.1093/schbul/sbq068. ISSN 0586-7614.
  4. ↑ Artaloytia, Juan Francisco; Arango, Celso; Lahti, Adrienne; Sanz, Javier; Pascual, Ana; Cubero, Pedro; Prieto, David; Palomo, Tomás (2006). "Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers". American Journal of Psychiatry. 163 (3): 488–493. doi:10.1176/appi.ajp.163.3.488. ISSN 0002-953X.
  5. ↑ Saeedi, H; Remington, G; Christensen, B (2006). "Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood". Schizophrenia Research. 85 (1-3): 222–231. doi:10.1016/j.schres.2006.03.033. ISSN 0920-9964.
  6. ↑ Lawn, Will; Freeman, Tom P; Pope, Rebecca A; Joye, Alyssa; Harvey, Lisa; Hindocha, Chandni; Mokrysz, Claire; Moss, Abigail; Wall, Matthew B; Bloomfield, Michael AP; Das, Ravi K; Morgan, Celia JA; Nutt, David J; Curran, H Valerie (2016). "Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses". Psychopharmacology. 233 (19-20): 3537–3552. doi:10.1007/s00213-016-4383-x. ISSN 0033-3158.
  7. ↑ Starcevic, Vladan (2014). "The reappraisal of benzodiazepines in the treatment of anxiety and related disorders". Expert Review of Neurotherapeutics. 14 (11): 1275–1286. doi:10.1586/14737175.2014.963057. ISSN 1473-7175.